Homologous recombination deficiency (HRD) is present in approximately 48% of ovarian cancer tumors,1 most often resulting from a mutation found only within the tumor. Some causes of HRD are well established, while others remain unknown.2,3,4
Determining HRD status for ovarian cancer patients can help provide information on the magnitude of benefit for PARP inhibitor therapy, which provide optimal outcomes to HRD positive patients.
Unidentified causes of HRD will be missed.
There is a distinct genomic effect associated with HRD.3 Evaluating LOH, TAI and LST allows for the assessment of HRD regardless of the specific cause.3
MyChoice examines ovarian cancer tumors using two methods (BRCA1/2 mutation and genomic instability) to determine a patient’s HRD status.
BRCA1 & BRCA2 status
Sequence variants + Large rearrangements
Genomic instability status
LOH + TAI + LST
MyChoice identifies 34% more tumors with HRD than tests that use %LOH alone.5
Clinicians will get a MyChoice result back within 2–3 weeks after the pathology lab receives the sample.
Easy-to-read MyChoice results with GIS, BRCA1/BRCA2 interpretation, and combined results to inform treatment decisions.
FDA, PMDA, ASCO, NCCN and ESMO trust MyChoice.9-12
It has been shown that by using the methods below, MyChoice can identify 34% more tumors with HRD than other testing methods that use %LOH alone5 ensuring you have the most accurate information to make informed treatment decisions.
MyChoice is the only HRD test prospectively validated in three phase III studies for use in first-line treatment of ovarian cancer.14-18 Robust long-term data confirm MyChoice testing improves survival in patients with newly diagnosed advanced ovarian cancer who receive first-line treatment.14-18
MyChoice is validated for decentralized evaluation of HRD in academic local molecular pathology laboratories, following the results of a real-world validation study.19 This means wider access to precision medicine for patients with ovarian cancer worldwide.
Learn more about the study below or download the clinical summary.
Watch Myriad Genetics’ ESMO 2022 Industry Satellite Symposium where Dr. Kirsten Timms explains why clinical validation is key to choosing the right HRD test for your patient.
MyChoice CDx is named in guidelines and is the only HRD test with level of evidence 1A (LoE1A) validated in multiple phase III studies for first-line PARP inhibitor treatment in ovarian cancer.14-18
Somatic testing should prioritize identification of molecular alterations that inform the use of effective interventions. This includes assessing BRCA1/2, loss of heterozygosity (LOH), or homologous recombination deficiency (HRD) status in the absence of a germline BRCA mutation.
Myriad MyChoice CDx is included in the new recommendations from The American Society of Clinical Oncology (ASCO) on the use of PARP inhibitors for the treatment and management of certain patients with advanced ovarian cancer.
Validated scar-based HRD tests can be used to guide PARP inhibitor treatment. ESMO recognizes MyChoice CDx is the only scar based HRD test validated in the first-line maintenance setting.
Note that for local testing, each MyChoice performing lab can provide its own reports, which may look different than the original report shown here.
MyChoice HRD Companion Diagnostic Test is available in many countries all over the world either via local labs in your country or via Myriad Genetics’ central laboratory in Salt Lake City, USA.
Please find further information at the link below on availability in different regions and links to relevant information and forms.